Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B

Early declines in serum hepatitis B surface (HBsAg) levels, their optimal cutoffs, and association with therapeutic endpoints in chronic hepatitis B (CHB) patients receiving entecavir treatment remain unclear. We prospectively enrolled 529 patients (195 hepatitis B e antigen [HBeAg]-positive and 334...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Cheng-Yuan, Lai, Hsueh-Chou, Su, Wen-Pang, Lin, Chia-Hsin, Chuang, Po-Heng, Chen, Sheng-Hung, Chen, Ching-Hsiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318891/
https://www.ncbi.nlm.nih.gov/pubmed/28220833
http://dx.doi.org/10.1038/srep42879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318891/
https://www.ncbi.nlm.nih.gov/pubmed/28220833
http://dx.doi.org/10.1038/srep42879

Ejemplares similares